NASDAQ:CCCC C4 Therapeutics (CCCC) Stock Price, News & Analysis $6.50 +0.06 (+0.93%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$6.49▼$6.9450-Day Range$4.05▼$7.3852-Week Range$1.06▼$11.88Volume1.36 million shsAverage Volume2.76 million shsMarket Capitalization$447.24 millionP/E RatioN/ADividend YieldN/APrice Target$8.71 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get C4 Therapeutics alerts: Email Address C4 Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.43 Rating ScoreUpside/Downside34.1% Upside$8.71 Price TargetShort InterestBearish16.90% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.27Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.56) to ($1.82) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.19 out of 5 starsMedical Sector795th out of 936 stocksBiological Products, Except Diagnostic Industry135th out of 154 stocks 3.2 Analyst's Opinion Consensus RatingC4 Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 3 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageC4 Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about C4 Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted16.90% of the outstanding shares of C4 Therapeutics have been sold short.Short Interest Ratio / Days to CoverC4 Therapeutics has a short interest ratio ("days to cover") of 7.Change versus previous monthShort interest in C4 Therapeutics has recently increased by 32.01%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldC4 Therapeutics does not currently pay a dividend.Dividend GrowthC4 Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CCCC. Previous Next 2.9 News and Social Media Coverage News SentimentC4 Therapeutics has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for C4 Therapeutics this week, compared to 2 articles on an average week.Search Interest15 people have searched for CCCC on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows4 people have added C4 Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, C4 Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.97% of the stock of C4 Therapeutics is held by insiders.Percentage Held by Institutions78.81% of the stock of C4 Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about C4 Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for C4 Therapeutics are expected to decrease in the coming year, from ($1.56) to ($1.82) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of C4 Therapeutics is -2.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of C4 Therapeutics is -2.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioC4 Therapeutics has a P/B Ratio of 1.60. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about C4 Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Awesomely, LLCAutomatic Income (from home)Everyone’s talking about this new income hack that could generate triple digit returns on your money. But here’s the best part…Watch this short video About C4 Therapeutics Stock (NASDAQ:CCCC)C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Read More CCCC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CCCC Stock News HeadlinesJuly 26 at 1:46 AM | americanbankingnews.comAnalysts Set C4 Therapeutics, Inc. (NASDAQ:CCCC) Target Price at $8.71July 23 at 10:45 PM | ca.finance.yahoo.comCCCC Oct 2024 3.000 putJuly 26, 2024 | MarketBeat (Ad)We just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.July 20, 2024 | ca.finance.yahoo.comPRAX Aug 2024 17.500 putJuly 16, 2024 | globenewswire.comC4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024July 8, 2024 | globenewswire.comC4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation DayJune 13, 2024 | seekingalpha.comC4 Therapeutics: Losing Steam And Presenting An OpportunityJune 10, 2024 | globenewswire.comC4 Therapeutics Appoints Ron Cooper as Chairman of the Board of DirectorsJuly 26, 2024 | MarketBeat (Ad)We just added a $300 account credit to your MarketBeat subscriptionMarketBeat All Access is our complete suite of portfolio monitoring software, research tools, stock screeners, proprietary reports, and more. Upgrade today and get $300 off your 2024-2025 subscription. Free for 30 days.May 22, 2024 | finance.yahoo.comWe Think C4 Therapeutics (NASDAQ:CCCC) Can Afford To Drive Business GrowthMay 17, 2024 | finance.yahoo.comC4 Therapeutics, Inc. (CCCC)May 13, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: C4 Therapeutics (CCCC), ACADIA Pharmaceuticals (ACAD) and Disc Medicine (IRON)May 10, 2024 | finance.yahoo.comC4 Therapeutics Inc (CCCC) Q1 2024 Earnings: Navigating Challenges with Strategic CollaborationsMay 9, 2024 | markets.businessinsider.comC4 Therapeutics: Hold Rating Maintained Amidst Encouraging Drug Progress and Stable FinancialsMay 9, 2024 | markets.businessinsider.comKey Takeaways From C4 Therapeutics Analyst RatingsMay 8, 2024 | investorplace.comCCCC Stock Earnings: C4 Therapeutics Misses EPS, Misses Revenue for Q1 2024May 8, 2024 | globenewswire.comC4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsApril 30, 2024 | finanznachrichten.deC4 Therapeutics, Inc.: C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)See More Headlines Receive CCCC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for C4 Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/26/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CCCC CUSIPN/A CIK1662579 Webwww.c4therapeutics.com Phone617-231-0700FaxN/AEmployees150Year FoundedN/APrice Target and Rating Average Stock Price Target$8.71 High Stock Price Target$16.00 Low Stock Price Target$2.00 Potential Upside/Downside+34.1%Consensus RatingHold Rating Score (0-4)2.43 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-132,490,000.00 Net Margins-629.24% Pretax Margin-622.85% Return on Equity-52.85% Return on Assets-34.01% Debt Debt-to-Equity RatioN/A Current Ratio5.08 Quick Ratio5.08 Sales & Book Value Annual Sales$20.04 million Price / Sales22.32 Cash FlowN/A Price / Cash FlowN/A Book Value$4.07 per share Price / Book1.60Miscellaneous Outstanding Shares68,806,000Free Float63,322,000Market Cap$447.24 million OptionableOptionable Beta3.07 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Andrew J. Hirsch M.B.A. (Age 53)CEO, President & Director Comp: $971kDr. Kenneth C. Anderson M.D. (Age 73)Ph.D., Co-Founder, Independent Director & Member of Scientific Advisory Board Comp: $39.03kDr. Stewart Fisher (Age 57)Chief Scientific Officer Comp: $657.34kMr. Scott N. Boyle M.B.A. (Age 46)Ph.D., Chief Business Officer Comp: $672.78kDr. Nathanael S. Gray Ph.D.Co-Founder & Member of Scientific Advisory BoardMs. Kendra AdamsChief Financial OfficerMr. Mark Mossler (Age 51)Chief Accounting Officer Ms. Jolie M. Siegel J.D. (Age 47)Chief Legal Officer & Corporate Secretary Comp: $610.4kMs. Kelly A. Schick (Age 44)Chief People Officer Dr. Isabel Chiu Ph.D.Senior Vice President of Strategic Alliances & Business DevelopmentMore ExecutivesKey CompetitorsInhibrxNASDAQ:INBXCompugenNASDAQ:CGENNurix TherapeuticsNASDAQ:NRIXBioCryst PharmaceuticalsNASDAQ:BCRXVir BiotechnologyNASDAQ:VIRView All CompetitorsInstitutional OwnershipBank of New York Mellon CorpBought 190,761 shares on 7/26/2024Ownership: 0.277%Hennion & Walsh Asset Management Inc.Bought 142,832 shares on 7/20/2024Ownership: 0.208%Lynx1 Capital Management LPBought 500,266 shares on 5/30/2024Ownership: 5.282%Farallon Capital Management LLCBought 28,000 shares on 5/24/2024Ownership: 0.041%Walleye Trading LLCBought 2,200 shares on 5/17/2024Ownership: 0.000%View All Institutional Transactions CCCC Stock Analysis - Frequently Asked Questions How have CCCC shares performed this year? C4 Therapeutics' stock was trading at $5.65 at the start of the year. Since then, CCCC shares have increased by 15.0% and is now trading at $6.50. View the best growth stocks for 2024 here. How were C4 Therapeutics' earnings last quarter? C4 Therapeutics, Inc. (NASDAQ:CCCC) released its quarterly earnings data on Wednesday, May, 8th. The company reported ($0.41) EPS for the quarter, hitting the consensus estimate of ($0.41). The firm earned $3.04 million during the quarter, compared to the consensus estimate of $10.93 million. C4 Therapeutics had a negative net margin of 629.24% and a negative trailing twelve-month return on equity of 52.85%. When did C4 Therapeutics IPO? C4 Therapeutics (CCCC) raised $150 million in an initial public offering (IPO) on Friday, October 2nd 2020. The company issued 8,800,000 shares at $16.00-$18.00 per share. Jefferies, Evercore ISI, BMO Capital Markets and UBS Investment Bank served as the underwriters for the IPO. Who are C4 Therapeutics' major shareholders? C4 Therapeutics' top institutional investors include Bank of New York Mellon Corp (0.28%) and Hennion & Walsh Asset Management Inc. (0.21%). Insiders that own company stock include Andrew Hirsch, Stewart Fisher, Jolie Siegel, Elena Prokupets, Adam Crystal and Malcolm Salter. View institutional ownership trends. How do I buy shares of C4 Therapeutics? Shares of CCCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CCCC) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding C4 Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share C4 Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
